Related Experiment Video
Updated: Jun 16, 2026
09:12
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
Neutralization of Clostridium difficile toxin A using antibody combinations.
Stephen J Demarest1, Mangala Hariharan, Marikka Elia
1Verenium Corp., San Diego, CA, USA. stephen.demarest@biogenidec.com
Mabs
|February 13, 2010
Summary
Monoclonal antibodies targeting Clostridium difficile toxin A
Area of Science:
- Microbiology
- Immunology
- Toxicology
Background:
- Clostridium difficile infection is a significant healthcare concern, primarily driven by toxins A and B.
- The cell wall binding (CWB) domains of these toxins are crucial for their adherence to host cells.
Purpose of the Study:
- To develop and evaluate murine monoclonal antibodies against the CWB domain of Clostridium difficile toxin A.
- To assess the neutralizing capacity of these antibodies, both individually and in combination.
Main Methods:
- Generation of murine monoclonal antibodies against the CWB domain of Clostridium difficile toxin A.
- Screening antibodies for their ability to neutralize toxin A.
- Investigating the mechanisms of neutralization, including surface coverage and inhibition of cell association.
Main Results:
- Three antibodies neutralized toxin A, recognizing multiple epitopes, suggesting surface coverage is important.
- A combination of two non-competing antibodies (3358 and 3359) demonstrated enhanced neutralization.
- Antibody 3358 increased detectable CWB domain presence, while 3359 inhibited CWB domain cell association.
Conclusions:
- Antibody combinations targeting broader epitope spaces on C. difficile toxin A's CWB domains offer enhanced neutralization.
- Multiple mechanisms, including increased surface coverage and inhibition of cell association, contribute to effective toxin neutralization.
- These findings suggest a promising strategy for developing improved therapeutics against C. difficile-associated diarrhea.
Related Concept Videos
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:17Antidotes
Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...